Anzu-cel is named as an intervention in 2 current clinical trials in our USA, UK, Germany, France, Netherlands, Canada and Israel registers. 2 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Immatics US, Inc. The most-studied condition is Melanoma, Cutaneous Malignant. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126 · ClinicalTrials.gov ↗ · Melanoma, Cutaneous Malignant
|
Phase 3 | Recruiting | Immatics US, Inc | UK, USA, Germany, France, Netherlands, Canada, Israel |
|
ACTengine® IMA203 Combined With mRNA-4203
NCT06946225 · ClinicalTrials.gov ↗ · Cutaneous Melanoma, Synovial Sarcoma
|
Phase 1 | Recruiting | Immatics US, Inc | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Anzu-cel. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors
2026-525827-25-00 · Neoplasms
|
Phase 1 | Authorised | Immatics US Inc | Germany |
| Lead sponsor | Trials |
|---|---|
| Immatics US, Inc | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in Germany | 1 | 1 |
| Clinical trials in France | 1 | 1 |
| Clinical trials in Netherlands | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Israel | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our USA, UK, Germany, France, Netherlands, Canada and Israel registers name Anzu-cel (also registered as IMA203) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 1 with sites in UK, 1 with sites in Germany, 1 with sites in France, 1 with sites in Netherlands, 1 with sites in Canada and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Immatics US, Inc. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Anzu-cel works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anzu-cel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anzu-cel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.